Agilent Technologies Inc.
History
| Year | Detail |
|---|---|
| 1966 | HP Laboratories is formed, which would eventually become Agilent Labs. |
| Company develops GaAsP (gallium-arsenide-phosphide) light-emitting diodes (LEDs). | |
| 1999 | HP created an independent measurement company composed of test and measurement components. |
| Agilent Technologies, the name of the new measurement company, is announced at historic brand-identity launch event in San Jose, California. | |
| 2000 | On June 2, 2000, Agilent Technologies becomes a fully independent company. |
| The introduction of Agilent’s Photonic Switching Platform accelerates the development of all-optical networks. | |
| 2001 | Agilent acquired Objective System Integrators Inc. (OSI). |
| Philips acquires Agilent Technologies’ Healthcare Solutions Group. | |
| 2002 | Agilent acquires RedSwitch. |
| 2003 | Agilent introduces miniature camera modules for camera-enabled mobile phones. |
| 2004 | Agilent's Visual Engineering Environment (VEE) Pro system-development software provides the interface to test communication equipment in the Mars Exploration Rovers. |
| Agilent acquires Silicon Genetics. | |
| 2005 | Agilent forms joint venture, Chengdu Instruments Division. |
| 2006 | Yokogawa Analytical Systems becomes a wholly owned subsidiary of Agilent Technologies. |
| Agilent introduces the E4898A Bit Error Ratio Tester (BERT). | |
| Agilent introduces the MXA signal analysis platform. | |
| 2007 | Agilent acquires Stratagene. |
| Agilent introduces the 7890A Gas Chromatograph platform. | |
| 2008 | Agilent introduces the 6230 Accurate-Mass time-of-flight liquid chromatograph/mass spectrometer (LC/MS) system. |
| 2009 | Agilent gets comprised of three business groups -- Life Sciences (LSG), Chemical Analysis (CAG) and Electronic Measurement (EMG). |
| Agilent introduces the industry's first microwave signal generator. | |
| 2010 | Agilent purchases Varian, Inc., the largest acquisition to date in the company's history. |
| Agilent and the National Center for Food Safety and Technology (NCFST) enter into a collaboration. | |
| 2011 | Agilent collaborates with Synthetic Biology Institute at UC Berkeley. |
| 2012 | Dako, becomes the largest acquisition in Agilent's history. |
| 2013 | On Sept. 19, Agilent announces the company will separate into two public companies, one comprising the life sciences, diagnostics and applied markets (LDA) businesses. |
| 2014 | Agilent completes the spinoff of its former electronic measurement business—Keysight Technologies-on Nov. 1. |
| Agilent creates the CrossLab Group. | |
| 2015 | Agilent acquires Seahorse Bioscience. |
| Agilent introduces GC/MSD system. | |
| Agilent launches the 6470 Triple Quadrupole Mass Spectrometer. | |
| Agilent introduces the new 6545 Q-TOF Mass Spectrometry system. | |
| 2016 | Agilent introduces a new Atomic Spectroscopy Platform for multiple analytical applications. |
| Agilent introduces InfinityLab. | |
| 2017 | Agilent acquires Cobalt Light System. |
| Agilent introduces the GC/Q-TOF System. | |
| Agilent launches new research-grade 6495B Triple Quadrupole LC/MS system. | |
| Agilent launches AdvanceBio LC/Q-TOF MS 6545XT system. | |
| 2018 | Agilent acquires privately held Advanced Analytical Technologies, Inc. |
| Agilent acquires Ireland-based Luxcel Biosciences. | |
| 2019 | In partnership with Merck & Co., Agilent gains approval of its first PD-L1 companion diagnostic in China. |
| Agilent acquires BioTek. | |
| Agilent introduces the InfinityLab LC/MSD iQ System. | |
| 2020 | Agilent receives FDA approval for PD-L1 IHC 22C3 pharmDx in Triple-Negative Breast Cancer. |
| Agilent launches its first-ever instrument subscription program. | |
| 2021 | Agilent launches three InfinityLab Bio LC systems. |
| Agilent and Visopharm expand their collaboration with a worldwide distribution agreement. | |
| 2022 | Agilent introduces the 6475 triple quadrupole LC/MS system. |
| Agilent acquires powerful AI and machine learning software for GC/MS platforms. | |
| 2023 | Agilent announces a doubling of manufacturing capacity of nucleic acid-based therapeutics. |
BCC Research Beacon